The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.
In this video, David takes a closer look at two biotechs that have seen big sell-offs recently. Savient has struggled with the launch of its gout drug Krystexxa, while Dynavax prepares to launch its hepatitis-B vaccine. Investors love to buy a bargain, but are these two stocks falling knives destined to cut investors? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
David Williamson owns shares of Dendreon. The Motley Fool owns shares of AstraZeneca and Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Has Savient Pharmaceuticals Become the Perfect Stock?
Finding companies that have all the right stuff can produce winners.
These 2 Stocks Stopped the Presses
These companies made big headlines -- what does it mean to you?